A Study of Brain Receptor Occupancy in Healthy Subjects

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Analgesics, Opioid; Aticaprant

Criteria

Inclusion Criteria:

• Healthy male or female

• Have clinical laboratory tests within normal reference ranges

• Have arterial and venous access sufficient to allow blood sampling

Exclusion Criteria:

• Currently enrolled in, or discontinued within the last 30 days from a clinical trial

• History of severe allergies or multiple adverse drug reactions

• Have an abnormal ECG at screening visit

• Have abnormal sitting blood pressure

• Have an increased risk of seizures

• Current suicidal ideation

• Positive test for HIV, hepatitis C, or hepatitis B

• Women who are breast feeding

• Smoke more than 10 cigarettes per day, or equivalent

• Drink more than 5 cups of coffee per day, or equivalent

• Have a history of head injury

• Unable to undergo a MRI

• Suffer from claustrophobia